Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system

By Fries L.F.   Tartaglia J.   Taylor J.   Kauffman E.K.   Meignier B.   Paoletti E.   Plotkin S.  

Vaccine, Vol. 14, Iss. 5, 1996-04 ,pp. : 428-434

Elsevier

Access to resources Recommend Favorite

Biological and immunogenic properties of rabies virus glycoprotein expressed by canine herpesvirus vector

By Xuan X.   Tuchiya K.   Sato I.   Nishikawa Y.   Onoderaz Y.   Takashima Y.   Yamamoto A.   Katsumata A.   Iwata A.   Ueda S.   Mikami T.   Otsuka H.  

Vaccine, Vol. 16, Iss. 9, 1998-05 ,pp. : 969-976

Elsevier

Access to resources Recommend Favorite

Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate

By Gonczol E.   Berencsi K.   Pincus S.   Endresz V.   Meric C.   Paoletti E.   Plotkin S.A.  

Vaccine, Vol. 13, Iss. 12, 1995-08 ,pp. : 1080-1085

Elsevier

Access to resources Recommend Favorite

The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys

By Skiadopoulos M.H.   Tatem J.M.   Surman S.R.   Mitcho Y.   Wu S.-L.   Elkins W.R.   Murphy B.R.  

Vaccine, Vol. 20, Iss. 13, 2002-03 ,pp. : 1846-1852

Elsevier

Access to resources Recommend Favorite

Immunogenic and protective properties of haemagglutinin protein (H) of Rinderpest virus expressed by a recombinant baculovirus

By Naik S.   Renukaradhya G.J.   Rajasekhar M.   Shaila M.S.  

Vaccine, Vol. 15, Iss. 6, 1997-04 ,pp. : 603-607

Elsevier

Access to resources Recommend Favorite